Natural killer (NK) cells were so named for their uniqueness in killing certain tumor and virus-infected cells without prior sensitization unlike T lymphocytes. NK cells possess a myriad of activation receptors and cytokine receptors that allow them to recognize stress ligands on infected/tumor cells and respond to the cytokines produced during the inflammatory process. Upon activation, NK cells produce pro-inflammatory cytokines, cytotoxic granules and chemokines to recruit other cells which ultimately result in killing of target cells. These functions of NK cells are modulated in vivo by several immune mediators; IL-15 being the most potent in enabling NK cell homeostasis, maturation and activation. Indeed, IL-15 knockout mice have no detectable NK cells. During microbial infections, NK cells stimulated with IL-15 display enhanced cytokine responses. This priming effect has previously been shown with respect to increased IFN-γ production in NK cells upon IL-12 and IL-15/IL-2 co-stimulation. In this study, I explored if this effect of IL-15 priming can be extended to other cytokines and observed enhanced NK cell responses to stimulation with IFN-, IL-21, IL-2 and IL-4 in addition to IL-12. Notably, we also observed elevated IFN-γ production in primed NK cells upon stimulation through the Ly49H activation receptor. IL-15 treatments induced NK cell proliferation, enhanced NK cell responses to activating stimuli and equipped them with cytotoxic granules thereby “readying” them for battle against infections and tumors. Here, we try to understand the signaling mechanisms underlying IL-15 treatments that activate NK cells. Currently, the fundamental processes required for priming and whether these signaling pathways work collaboratively or independently for NK cell functions are poorly understood. To identify the key signaling events, we examined IL-15 priming on NK cells in which the pathways emanating from IL-15 receptor activation were blocked with specific inhibitors. Our results demonstrate that the PI3K-AKT-mTOR pathway is indispensable for cytokine responses in IL-15 primed NK cells. Furthermore, this pathway is also implicated in a broad range of IL-15 induced NK cell effector functions such as proliferation and cytotoxicity. Given that NK cells are critical for control of viral infections like murine cytomegalovirus (MCMV), we decided to analyze the consequences of blocking the PI3K-AKT-mTOR pathway in NK cells on its anti-viral responses. Likewise, NK cells from mice treated with rapamycin to block the mTOR pathway displayed defects in proliferation, IFN-γ and granzyme B production resulting in elevated viral burdens upon MCMV infection. Taken together, our data demonstrates the requirement of PI3K-mTOR pathway for enhanced NK cell functions by IL-15. It also shows that IL-15 primes NK cell responses to several cytokines and to Ly49H activation receptor stimulation. To our knowledge this is first report to demonstrate the requirement of mTOR activity in NK cells for efficient control of acute MCMV infections; thereby coupling the metabolic sensor mTOR to NK cell anti-viral responses.

京都大学 / 新制・課程博士 / 博士(医学) / 甲第23058号 / 医博第4685号 / 新制||医||1048(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 妻木 範行, 教授 浅野 雅秀, 教授 別所 和久 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

No description available.

In den letzten Jahren wurde gezeigt, dass die Serumkonzentration des insulinähnlichen Wachstumsfaktorbindungsproteins-2 (IGFBP-2) bei Krebserkrankungen, die mit dem Verlust des Tumorsuppressorgens PTEN einhergehen, erhöht ist und daher möglicherweise einen Marker für den PTEN-Status und die Aktivität des PI3K/AKT/mTOR-Signalweges darstellt. Schmid et al. haben 2014 einen Patienten mit PTEN-Hamartom-Tumor-Syndrom (PHTS) mit einer heterozygoten PTEN-Keimbahndeletion und massiver Lipomatose beschrieben, bei dem erhöhte IGFBP-2 Serumspiegel gemessen wurden. Ziel dieser Arbeit war es zu analysieren, ob PTEN-defiziente Lipomzellen des Patienten im Vergleich zu Kontrollfettzellen mehr IGFBP-2 produzieren, sowie den Einfluss verschiedener pharmakologischer Inhibitoren des AKT/PI3K/mTOR - und des MAPK- Signalwegs auf die IGFBP-2 Produktion zu untersuchen. In der PTEN-defizienten Lipomzellkultur, gewonnen aus reseziertem Lipomgewebe des Patienten, wurden vergleichbare Mengen an IGFBP-2 wie in den nicht PTEN-defizienten Kontrollzellen gefunden. Die pharmakologische Hemmung der PI3K und AKT bewirkten eine signifikante Senkung der IGFBP-2 Expression und Sekretion, wohingegen sich bei Hemmung der MEK und des mTORC1 keine Effekte zeigten. Diese Ergebnisse weisen darauf hin, dass eine heterozygote PTEN-Deletion in Lipomzellen nicht zu einer erhöhten IGFBP-2 Produktion führt und daher die erhöhten Serumspiegel des Patienten nicht darauf zurückzuführen sind. Des Weiteren bestätigen die in vitro Ergebnisse die klinische Beobachtung, dass unter der Therapie mit dem mTORC1-Inhibitor Rapamycin die IGFBP-2 Serumspiegel des Patienten nicht zurückgingen. Möglicherweise stellt IGFBP-2 jedoch einen geeigneten Verlaufsmarker für eine Therapie mit PI3K- oder AKT-Inhibitoren dar.

published_or_final_version / abstract / Pathology / Master / Master of Philosophy

published_or_final_version / Surgery / Doctoral / Doctor of Philosophy

published_or_final_version / Surgery / Master / Master of Philosophy

Organ‐transplant recipients (OTRs) on a new class of immunosuppressants, rapamycin and its analogues, have reduced cutaneous Squamous Cell Carcinomas (cSCCs). Rapamycin, an mTORC1 inhibitor, is also a known autophagy inducer in experimental models. Autophagy, which literally means self‐eating, is a cell survival mechanism but can also lead to cell death. Therefore, the main hypothesis behind this work is that rapamycin prevents epidermal tumourigenesis by either affecting epidermal mTOR regulation of autophagy and/or selectively affecting epidermal AKT isoform activity. Epidermal keratinocytes move from the proliferating basal layer upwards to the granular layers where they terminally differentiate, forming a layer of flattened, anucleate cells or squames of the cornified layer which provides an essential environmental barrier. However, epidermal terminal differentiation, a specialised form of cell death involving organelle degradation, is poorly understood. The work presented in this thesis shows that analysis of the autophagy marker expression profile during foetal epidermal development, indicates autophagy is constitutively active in the terminally differentiating granular layer of epidermis. Therefore, I hypothesize that autophagy is a mechanism of organelle degradation during terminal differentiation of granular layer keratinocytes. In monolayer keratinocytes, activation of terminal differentiation is accompanied by autophagic degradation of nuclear material, nucleophagy. This suggests that constitutive autophagy is a pro‐death mechanism required for terminal differentiation. In cultured keratinocytes and in epidermal cultures, rapamycinmediated mTORC1 inhibition strongly increases AKT1 activity as well as up‐regulates constitutive granular layer autophagy promoting terminal differentiation. Therefore, autophagy is an important fundamental process in keratinocytes which may be the mechanism by which terminally differentiating keratinocytes of the epidermal granular layer degrade their organelles required for barrier formation. This may have implications for the treatment of patients with barrier defects like psoriasis. In immunosuppressed OTRs, rapamycin may promote epidermal autophagy and AKT1 activity adding to its anti‐tumourigenic properties.

The kinase mechanistic target of rapamycin (mTOR) is a regulator of cell growth and survival, protein synthesis-dependent synaptic plasticity, and macroautophagic degradation of cellular components. When active, mTOR induces protein translation and inhibits the protein and organelle degradation process of macroautophagy. Accordingly, when blocking mTOR activity with rapamycin, protein translation is blocked and macroautophagy is induced. In the literature, the effects of rapamycin are usually attributed solely to modulation of protein translation, and not macroautophagy. Nevertheless, mTOR also regulates synaptic plasticity directly through macroautophagy, and neurodegeneration may occur when this process is deficient. Macroautophagy degrades long-lived proteins and organelles via sequestration into autophagic vacuoles, and has been implicated in several human diseases including Alzheimer's, Huntington's and Parkinson's disease. Mice conditionally lacking autophagy-related gene (Atg) 7 function have been exploited to investigate the role of macroautophagy in particular mouse cell populations or entire organs. These studies have revealed that the ability to undergo macroautophagic turnover is required for maintenance of proper neuronal morphology and function. It remained unknown, however, whether it also modulates neurotransmission. We used the Atg7-deficiency model to explore the role of macroautophagy in two sites of the basal ganglia; 1) the dopaminergic neuron, and 2) the direct pathway medium spiny neuron. Briefly, we treated mice with rapamycin, and then examined whether an observed effect was present in control animals, but absent in macroautophagy-deficient lines. We found that rapamycin induces formation of autophagic vacuoles in striatal dopaminergic terminals, and that this is associated with decreased tyrosine hydroxylase (TH)+ axonal profile volumes, synaptic vesicle numbers, and evoked dopamine (DA) release. On the other hand, evoked DA secretion was enhanced and recovery was accelerated in transgenic animals in which the ability to undergo macroautophagy was eliminated in dopaminergic neurons by crossing a mouse line expressing Cre recombinase under the control of the dopamine transporter (DAT) promoter with another in which the Atg7 gene was flanked by loxP sites. Rapamycin failed to decrease evoked DA release or the number of dopaminergic synaptic vesicles per terminal area in the striatum of these mice. Our data demonstrated that mTOR inhibition, specifically through induction of macroautophagy, can rapidly alter presynaptic structure and neurotransmission. We then focused on elucidating the role of macroautophagy in dopaminoceptive neurons, the DA 1 receptor (D1R)-expressing medium spiny neuron. Mice were confirmed to be D1R-specific conditional macroautophagy knockouts as assessed by p62 aggregate accumulation in D1R-rich brain regions (striatum, prefrontal cortex, and the anterior olfactory nuclei), and by analysis of colocalization of Cre recombinase and substance P. Marked age-dependent differences in the presence of p62+ aggregates were noted when comparing the dorsal vs. ventral striatum, and at different ages. We found that the size of striatal postsynaptic densities (PSDs) are modulated by Atg7, as mutant mice have significantly larger PSDs. Surprisingly, we also observed an increase in DAT immunolabel in the dorsal striatum, which suggests that apart from increasing synaptic strength, lack of macroautophagy in postsynaptic neurons could indirectly lead to functional consequences in presynaptic dopaminergic function. Given the newly elucidated role of macroautophagy in modulating a number of pre- and post- synaptic properties, we then explored the potential implications of this process in mediating the effects of synaptic plasticity, specifically to that induced by recreational drugs. An array of studies demonstrates that drugs of abuse induce numerous forms of neuroplasticity in the basal ganglia. Among these changes, rodents that are chronically treated with psychostimulants show increases in dendritic spine density in striatal medium spiny neurons. Little is known about the molecular mechanisms underlying medium spiny neurons gaining more spines in response to psychostimulants. Also, most data, such as involvement of both the D1R and N-methyl-D-aspartic acid (NMDA) receptors, stems from studies using cocaine, and not amphetamine, although a single injection of cocaine has been shown to increase medium spiny neuron spine density, whether acute amphetamine is capable to do so remains to be elucidated. This is an attractive avenue of research to follow given that amphetamines are used recreationally, abused, but unlike cocaine, prescribed for attention deficit hyperactivity disorder and narcolepsy (reviewed in Heal et al., 2013). A myriad of studies has implicated these two proteins in spinogenesis, spine maturation and maintenance, and neuroplasticity. In addition, several studies have demonstrated an association between levels of PSD95 and spine density in various brain regions. Before characterizing the role of mTOR and macroautophagy in psychostimulant-induced plasticity, we examined if an acute injection of amphetamine at multiple doses (1-30 mg/kg) and times of collection after treatment (1-48 hr) influences PSD95 and Homer1b/c in the striatum of wild-type mice by western blotting. We found that amphetamine failed to robustly modify levels of either protein in the striatum. Our data raises several possibilities, including the possibility that unlike cocaine, acute regimens of amphetamine might not regulate spine density in the striatum, and that, it is crucial to examine their effects separately. Finally, this work now provides a starting point to undertake the study of how acute amphetamine affects macroautophagic machinery that regulates molecular, morphological, functional and whole animal behavior.

Hydrogels have successfully proved themselves useful for drug delivery applications and several delivery routes have been developed over the years. The particular interest in this work was to design, synthesise and evaluate in situ forming drug eluting hydrogels, which have the potential to ameliorate the healing of cardiovascular diseases. With this aim the anti-inflammatory and immunosuppressant drugs rapamycin (Ra) and dexamethasone (Dex) were made water soluble by conjugation with polyethylene glycol (PEG). Ra was attached pendant from the terminal of PEGs while Dex was incorporated into dendritic structures grown from PEGs. These conjugates were further crosslinked into hydrogels by either conjugate or thiol-ene addition. The gel degradation was tuned to take between 5 and 27 days by using gel building block combinations that induced either 2 or 4 hydrolytically labile bonds per crosslink or by varying the number of crosslinking sites of the building blocks. The use of thiol-ene addition prolonged the degradation time nearly seven folded compared to conjugate addition as a more stable crosslink was formed. Two different formulations for gelling via conjugate addition were used (acrylate-thiol or vinyl sulphone-thiol) to deliver Ra, which was carried by either a 4- or 2-armed PEG. The elution kinetic for the respective gel formulation was of zero order during 15 and 19 days of gel degradation. In addition, Ra was PEGylated via esters, with a distance of either one or two carbons to a nearby thio-ether functionality. The difference in ester conjugation resulted in a slight but significant change in drug-PEG conjugate stability, which was mirrored by the increased time to reach the half amount of total drug elution; from 9.3 to 10.2 days and from 5.1 to 9.7 days for the two gel formulations, respectively. Dexamethasone was incorporated via an ester into dendrons of first and second generation pending from 2- and 4-armed PEGs at loadings of 2, 4 or 6 Dex molecules per carrier molecule. The resulting elution kinetic was of zero order during degradation periods of 5-27 days. Released Dex still possessed biological activity as determined by an in vitro cell assay. The novelties in this thesis are: (A) slow release of rapamycin obtained by covalent incorporation into hydrogels, (B) the use of unique PEG-based dendrimers to incorporate dexamethasone into a hydrogel and (C) zero order sustained release of dexamethasone at physiological pH. / Hydrogeler har framgångsrikt visat sig användbara för att leverera läkemedel och ett flertal metoder har utvecklats de senaste 20 åren. Fokuset i den här avhandlingen ligger på att designa, framställa och utvärdera läkemedelsutsöndrande hydrogeler som spontanhärdar in situ, vilka har potential att förbättra läkningen efter kardiovaskulär sjukdom. Med det syftet gjordes de anti-inflammatoriska och immunsänkande läkemedlen rapamycin (Ra) och dexametason (Dex) vattenlösliga genom att konjugeras med polyetylenglygol (PEG). Ra fästes kovalent längst ut på PEGar medans Dex inkluderades i dendritiska strukturer vilka byggdes från ändpunkten av PEGar. De här konjugaten tvärbands till hydrogeler via antingen konjugerad addition eller radikal polymerisation. Nedbrytningen av gelerna trimmades till att ta mellan 5 och 27 dagar genom att använda kombinationer av gelbyggstenar som bildar antingen 2 eller 4 hydrolyserbara estrar per tvärbindning eller genom att variera antalet tvärbindningspunkter hos byggstenarna. Användandet av radikal polymerisation i sig ledde till att nedbrytningen av geler tog nära sju gånger längre tid jämfört med geler gjorda via konjugerad addition eftersom stabilare tvärbindningar då formas. Två olika kombinationer för härdning via konjugerad addition (akryl-tiol eller vinylsulfon-tiol) användes för att leverera Ra som bars av antingen en 4- eller 2-armad PEG. Utsöndringskinetiken av Ra för de två kombinationerna var av nollte ordningen under de 15 och 19 dagar som gelerna degraderade. Dessutom, Ra PEGylerades via estrar med ett avstånd på antingen ett eller två kol till en närliggande tioeter. Skillnaden i avstånd ledde till en liten men signifikant skillnad i stabiliteten hos Ra-PEG konjugaten, vilket speglades i den förlängda tiden att nå halva mängden av den totala läkemedelsutsöndringen; från 9.3 till 10.2 dagar och från 5.1 till 9.7 dagar för de två respektive gelkombinationerna. Dex kopplades in via en esterbindning till dendroner av första och andra generationen byggda från PEGar med 2 eller 4 armar, vilket resulterade i att 2, 4 eller 6 Dex levererades per bärarmolekyl. Dex eluerade med nollte ordningens kinetik under degraderingsperioder på mellan 5 och 27 dagar. Vidbehålllen biologisk aktivitet av eluerad Dex bekräftades genom cellexperiment in vitro. Nyheterna i den här avhandlingen består av: (A) kontrollerad utsöndring av rapamycin uppnådd genom kovalent inbindning till hydrogeler, (B) användandet av unika PEGbaserade dendrimerer för kovalent inbindning av dexametason till hydrogeler och (C) nollte ordningens utsöndring av dexametason vid fysiologiskt pH. / <p>QC 20130204</p>